{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:18:20Z","timestamp":1791332300767,"version":"4.3.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Schizophrenia is a complex psychiatric disorder, and in patients treated with clozapine, it may induce or exacerbate obsessive-compulsive symptoms (OCS), which negatively affect patients\u2019 quality of life, functionality and treatment adherence. Despite its clinical relevance, the reported prevalence and characteristics of clozapine associated OCS vary widely, limiting effective management.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>This scoping review synthesizes evidence on the prevalence of OCS in patients with schizophrenia treated with clozapine and explores treatment characteristics (types, severity, dose, and time to onset\/exacerbation).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The PRISMA-ScR methodology guided the search in PubMed, LILACS, Embase, and Scielo. Observational studies in Spanish, English, Portuguese, and French reporting prevalence, incidence, or frequency of OCS in patients over 18 years with schizophrenia treated with clozapine were included. Clinical, qualitative studies, and those with access restrictions were excluded. Risk of bias was assessed using JBI tools.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Fourteen studies were included, reporting OCS prevalence between 20% and 76%, and de novo OCS between 4.8% and 46.4%. Clozapine dose ranged from 196 to 525\u00a0mg\/day, and treatment duration from 5 to 210 months. The most common obsessions were aggression and checking, with severity ranging from mild to moderate.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The prevalence of OCS in patients treated with clozapine varies widely. Further research is needed to clarify the relationship between dose, treatment duration, and the onset\/exacerbation of OCS.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12888-024-06466-9","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T15:51:15Z","timestamp":1737647475000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Prevalence of obsessive-compulsive symptoms in patients with schizophrenia treated with clozapine: a scoping review"],"prefix":"10.1186","volume":"25","author":[{"given":"Evelyn","family":"Moreno Tarazona","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio","family":"Orozco Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"La Rosa Giron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Ruiz-Grosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Lazo-Porras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"6466_CR1","unstructured":"National Collaborating Centre for Mental Health (UK). Psychosis and schizophrenia in adults: treatment and management: updated edition 2014. London: National Institute for Health and Care Excellence (UK). 2014. (NICE Clinical Guidelines, No. 178.) 2, Psychosis and schizophrenia in adults. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK333029\/ Accessed 28 Aug 2024."},{"key":"6466_CR2","unstructured":"National Institute for Health and Care Excellence (NICE). Psychosis and schizophrenia in adults: prevention and management. London: National Institute for Health and Care Excellence (NICE); 2014 Mar. (NICE Clinical Guidelines, No. 178.) Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK555203\/ Accessed 25 Aug 2024."},{"key":"6466_CR3","unstructured":"Manassa H, Rehman B, Rizvi A, Chapman J. Schizophrenia. [Updated 23 Feb 2024]. En: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; Jan 2024\u2013. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK539864\/"},{"key":"6466_CR4","doi-asserted-by":"crossref","unstructured":"McDonagh MS, Dana T, Selph S, Devine EB, Cantor A, Bougatsos C et al. Treatments for schizophrenia in adults: a systematic review [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2017 Oct. (Comparative Effectiveness Review, No. 198). Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK487628\/","DOI":"10.23970\/AHRQEPCCER198"},{"key":"6466_CR5","doi-asserted-by":"publisher","unstructured":"V\u00edlchez Salcedo LA, Turco Ar\u00e9valo E, Varillas Mar\u00edn RA, Salgado Valenzuela CA, Salazar de la Cruz M, Huam\u00e1n S\u00e1nchez K et al. El abordaje temprano y tratamiento mixto en el manejo de la esquizofrenia: Gu\u00eda de pr\u00e1ctica cl\u00ednica basada en evidencia de un hospital especializado en salud mental del Ministerio de Salud del Per\u00fa. An Fac Med. 2019;80(3):389\u2009\u2013\u200996. Available from: https:\/\/doi.org\/10.15381\/anales.803.1686","DOI":"10.15381\/anales.803.1686"},{"key":"6466_CR6","unstructured":"Pike E, Leiknes KA, Wisl\u00f8ff T, Ringerike T, Klemp M. Efficacy and safety of first-generation and second-generation antipsychotic drugs for schizophrenia in adults. An overview of systematic reviews [Internet]. Oslo: Norwegian Knowledge Centre for the Health Services;, Rapport. 08). Available from: https:\/\/www.fhi.no\/en\/publ\/2009-and-older\/efficacy-and-safety-of-first-generation-and-second--generation-anti-psychot\/"},{"key":"6466_CR7","doi-asserted-by":"publisher","unstructured":"Mayoral-van Son J, de la Foz VO-G, Martinez-Garcia O, Moreno T, Parrilla-Escobar M, Valdizan EM et al. Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study. J Clin Psychiatry. 2016;77(4):492\u2013500. Available from: https:\/\/doi.org\/10.4088\/JCP.14m09540","DOI":"10.4088\/JCP.14m09540"},{"key":"6466_CR8","doi-asserted-by":"publisher","unstructured":"Agid O, Crespo-Facorro B, de Bartolomeis A, Fagiolini A, Howes OD, Sepp\u00e4l\u00e4 N, Correll CU. Overcoming the barriers to identifying and managing treatment-resistant schizophrenia and to improving access to clozapine: a narrative review and recommendation for clinical practice. Eur Neuropsychopharmacol. 2024;84:35\u201347. https:\/\/doi.org\/10.1016\/j.euroneuro.2024.04.012. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0924977X24000956","DOI":"10.1016\/j.euroneuro.2024.04.012"},{"issue":"5","key":"6466_CR9","doi-asserted-by":"publisher","first-page":"448","DOI":"10.47626\/1516-4446-2023-3126","volume":"45","author":"E Diniz","year":"2023","unstructured":"Diniz E, Fonseca L, Rocha D, Trevizol A, Cerqueira R, Ortiz B, et al. Treatment resistance in schizophrenia: a meta-analysis of prevalence and correlates. Rev Bras Psiquiatr. 2023;45(5):448\u201358. https:\/\/doi.org\/10.47626\/1516-4446-2023-3126.","journal-title":"Rev Bras Psiquiatr"},{"issue":"15","key":"6466_CR10","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.1017\/S0033291716002014","volume":"46","author":"J Lally","year":"2016","unstructured":"Lally J, Ajnakina O, Di Forti M, Trotta A, Demjaha A, Kolliakou A, et al. Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. Psychol Med. 2016;46(15):3231\u201340. https:\/\/doi.org\/10.1017\/S0033291716002014.","journal-title":"Psychol Med"},{"key":"6466_CR11","doi-asserted-by":"crossref","unstructured":"Goodman WK, Grice DE, Lapidus KAB, Coffey BJ. Obsessive-compulsive disorder. Psychiatr Clin North Am. 2014;37(3):257\u2009\u2013\u200967. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/25150561\/","DOI":"10.1016\/j.psc.2014.06.004"},{"key":"6466_CR12","unstructured":"Sadock BJ, Sadock VA. Trastorno obsesivo-compulsivo. En: Kaplan & Sadock. Sinopsis de psiquiatr\u00eda. 11a ed. La Ciudad Condal, Espa\u00f1a: Lippincott Williams & Wilkins; 2015. pp. 918\u2013961."},{"key":"6466_CR13","doi-asserted-by":"publisher","unstructured":"Vellosillo PS, Vicario AF-C. Trastorno obsesivo compulsivo. Medicine [Internet]. 2015;11(84):5008\u201314. Available from: https:\/\/doi.org\/10.1016\/j.med.2015.07.010","DOI":"10.1016\/j.med.2015.07.010"},{"key":"6466_CR14","doi-asserted-by":"publisher","unstructured":"Schirmbeck F, Zink M. Comorbid obsessive-compulsive symptoms in schizophrenia: contributions of pharmacological and genetic factors. Front Pharmacol [Internet]. 2013;4. Available from: https:\/\/doi.org\/10.3389\/fphar.2013.00099","DOI":"10.3389\/fphar.2013.00099"},{"issue":"11","key":"6466_CR15","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.4088\/jcp.11m07164","volume":"73","author":"AAS Beduin","year":"2012","unstructured":"Beduin AAS, Swets M, Machielsen M, Korver N. Obsessive-compulsive symptoms in patients with schizophrenia. J Clin Psychiatry. 2012;73(11):1395\u2013402. https:\/\/doi.org\/10.4088\/jcp.11m07164.","journal-title":"J Clin Psychiatry"},{"key":"6466_CR16","doi-asserted-by":"publisher","unstructured":"Grover S, Hazari N, Chakrabarti S, Avasthi A. Relationship of obsessive compulsive symptoms\/disorder with clozapine: A retrospective study from a multispeciality tertiary care centre. Asian J Psychiatr [Internet]. 2015;15:56\u201361. Available from: https:\/\/doi.org\/10.1016\/j.ajp.2015.05.002","DOI":"10.1016\/j.ajp.2015.05.002"},{"key":"6466_CR17","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. The American psychiatric association practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association Publishing; 2020.","DOI":"10.1176\/appi.books.9780890424841"},{"key":"6466_CR18","doi-asserted-by":"crossref","unstructured":"Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJM, Birnbaum ML et al. Treatment-resistant schizophrenia: Treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry [Internet]. 2017;174(3):216\u201329. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/27919182\/","DOI":"10.1176\/appi.ajp.2016.16050503"},{"issue":"11","key":"6466_CR19","doi-asserted-by":"publisher","first-page":"840","DOI":"10.3390\/brainsci10110840","volume":"10","author":"AM Dragoi","year":"2020","unstructured":"Dragoi AM, Radulescu I, N\u0103sui BA, Pop AL, Varlas VN, Trifu S. Clozapine: an updated overview of pharmacogenetic biomarkers, risks, and Safety-particularities in the Context of COVID-19. Brain Sci. 2020;10(11):840. https:\/\/doi.org\/10.3390\/brainsci10110840. PMID: 33187329; PMCID: PMC7697202.","journal-title":"Brain Sci"},{"issue":"11","key":"6466_CR20","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1007\/s00277-020-04215-y","volume":"99","author":"A Mijovic","year":"2020","unstructured":"Mijovic A, MacCabe JH. Clozapine-induced agranulocytosis. Ann Hematol. 2020;99(11):2477\u201382. https:\/\/doi.org\/10.1007\/s00277-020-04215-y. [PubMed 32815018].","journal-title":"Ann Hematol"},{"issue":"1","key":"6466_CR21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3390\/pharmaceutics14010047","volume":"14","author":"KH Wills","year":"2021","unstructured":"Wills KH, Behan SJ, Nance MJ, Dawson JL, Polasek TM, Hopkins AM, van Dyk M, Rowland A. Combining therapeutic drug monitoring and pharmacokinetic modelling deconvolutes physiological and environmental sources of variability in Clozapine exposure. Pharmaceutics. 2021;14(1):47. https:\/\/doi.org\/10.3390\/pharmaceutics14010047. PMID: 35056943; PMCID: PMC8779032.","journal-title":"Pharmaceutics"},{"key":"6466_CR22","doi-asserted-by":"publisher","unstructured":"Schirmbeck F, Rausch F, Englisch S, Eifler S, Esslinger C, Meyer-Lindenberg A et al. Differential effects of antipsychotic agents on obsessive-compulsive symptoms in schizophrenia: a longitudinal study. J Psychopharmacol. 2013;27(4):349\u2009\u2013\u200957. Available from: https:\/\/doi.org\/10.1177\/0269881112463470","DOI":"10.1177\/0269881112463470"},{"key":"6466_CR23","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1017\/S0033291711000419","volume":"41","author":"F Schirmbeck","year":"2011","unstructured":"Schirmbeck F, Esslinger C, Rausch F, Englisch S, Meyer-Lindenberg A, Zink M. Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia. Psychol Med. 2011;41:2361\u201373. https:\/\/doi.org\/10.1017\/S0033291711000419.","journal-title":"Psychol Med"},{"issue":"14","key":"6466_CR24","doi-asserted-by":"publisher","first-page":"989","DOI":"10.2165\/00023210-200418140-00004","volume":"18","author":"M Poyurovsky","year":"2004","unstructured":"Poyurovsky M, Weizman A, Weizman R. Obsessive-compulsive disorder in schizophrenia: clinical characteristics and treatment. CNS Drugs. 2004;18(14):989\u20131010.","journal-title":"CNS Drugs"},{"issue":"5","key":"6466_CR25","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1111\/j.1476-5381.2011.01638.x","volume":"165","author":"S Tanahashi","year":"2012","unstructured":"Tanahashi S, Yamamura S, Nakagawa M, Motomura E, Okada M. Clozapine, but not haloperidol, enhances glial D-serine and L-glutamate release in rat frontal cortex and primary cultured astrocytes. Br J Pharmacol. 2012;165(5):1543\u201355. https:\/\/doi.org\/10.1111\/j.1476-5381.2011.01638.x.","journal-title":"Br J Pharmacol"},{"key":"6466_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.psychres.2016.09.031","volume":"246","author":"D Grillault Laroche","year":"2016","unstructured":"Grillault Laroche D, Gaillard A. Induced obsessive-compulsive symptoms (OCS) in schizophrenia patients under atypical antipsychotics (AAPs): review and hypotheses. Psychiatry Res. 2016;246:119\u201328. https:\/\/doi.org\/10.1016\/j.psychres.2016.09.031.","journal-title":"Psychiatry Res"},{"key":"6466_CR27","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s11920-014-0510-8","volume":"16","author":"TM Fonseka","year":"2014","unstructured":"Fonseka TM, Richter MA, M\u00fcller DJ. Second generation antipsychotic-induced obsessive-compulsive symptoms in schizophrenia: a review of the experimental literature. Curr Psychiatry Rep. 2014;16:510. https:\/\/doi.org\/10.1007\/s11920-014-0510-8.","journal-title":"Curr Psychiatry Rep"},{"issue":"16","key":"6466_CR28","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1017\/S003329171800017X","volume":"48","author":"E Fernandez-Egea","year":"2018","unstructured":"Fernandez-Egea E, Worbe Y, Bernardo M, Robbins TW. Distinct risk factors for obsessive and compulsive symptoms in chronic schizophrenia. Psychol Med. 2018;48(16):2668\u201375. doi: 10.1017\/S003329171800017X. Epub 2018 Feb 19. PMID: 29455687; PMCID: PMC6236440.","journal-title":"Psychol Med"},{"key":"6466_CR29","doi-asserted-by":"crossref","unstructured":"Cardinal RN, Savulich G, Mann LM, Fern\u00e1ndez-Egea E. Association between antipsychotic\/antidepressant drug treatments and hospital admissions in schizophrenia assessed using a mental health case register. NPJ Schizophr [Internet]. 2015;1(1):1\u20137. Available from: https:\/\/www.nature.com\/articles\/npjschz201535","DOI":"10.1038\/npjschz.2015.35"},{"issue":"1","key":"6466_CR30","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/acps.13567","volume":"148","author":"BG Burk","year":"2023","unstructured":"Burk BG, DiGiacomo T, Polancich S, Pruett BS, Sivaraman S, Birur B. Antipsychotics and obsessive-compulsive disorder\/obsessive-compulsive symptoms: a pharmacovigilance study of the FDA adverse event reporting system. Acta Psychiatr Scand. 2023;148(1):32\u201346. https:\/\/doi.org\/10.1111\/acps.13567. Epub 2023 May 17. PMID: 37194481.","journal-title":"Acta Psychiatr Scand"},{"issue":"4","key":"6466_CR31","first-page":"211","volume":"32","author":"JA G\u00e1lvez-Buccollini","year":"2004","unstructured":"G\u00e1lvez-Buccollini JA, Fiestas F, Herrera P, Vega-Dienstmaier JM, Guimas B, Mazzotti G. S\u00edntomas obsesivo-compulsivos en Esquizofrenia Durante El tratamiento con clozapina y antipsic\u00f3ticos cl\u00e1sicos. Actas Esp Psiquiatr. 2004;32(4):211\u20135.","journal-title":"Actas Esp Psiquiatr"},{"key":"6466_CR32","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1159\/000505876","volume":"89","author":"DD Kim","year":"2020","unstructured":"Kim DD, Barr AM, Lu C, Stewart SE, White RF, Honer WG, et al. Clozapine-associated obsessive-compulsive symptoms and their management: a systematic review and analysis of 107 reported cases. Psychother Psychosom. 2020;89:151\u201360. https:\/\/doi.org\/10.1159\/000505876.","journal-title":"Psychother Psychosom"},{"issue":"8","key":"6466_CR33","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.euroneuro.2019.06.006","volume":"29","author":"M Biria","year":"2019","unstructured":"Biria M, Huang FX, Worbe Y, Fineberg NA, Robbins TW, Fernandez-Egea E. A cross sectional study of impact and clinical risk factors of antipsychotic-induced OCD. Eur Neuropsychopharmacol. 2019;29(8):905\u201313. https:\/\/doi.org\/10.1016\/j.euroneuro.2019.06.006.","journal-title":"Eur Neuropsychopharmacol"},{"key":"6466_CR34","unstructured":"Scoping. \u2014 [Internet]. PRISMA statement. [Accessed 2 September 2024]. Available from: https:\/\/www.prisma-statement.org\/scoping"},{"key":"6466_CR35","unstructured":"Shanaa A. Rayyan \u2013 intelligent systematic review [Internet]. Rayyan. Rayyan Systems; 2021 [Accessed 2 September 2024]. Available from: https:\/\/www.rayyan.ai"},{"issue":"8","key":"6466_CR36","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/0005-7967(96)00036-8","volume":"34","author":"G Steketee","year":"1996","unstructured":"Steketee G, Frost R, Bogart K. The Yale-Brown Obsessive compulsive scale: interview versus self-report. Behav Res Ther. 1996;34(8):675\u201384.","journal-title":"Behav Res Ther"},{"issue":"2","key":"6466_CR37","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1037\/a0018492","volume":"22","author":"EA Storch","year":"2010","unstructured":"Storch EA, Rasmussen SA, Price LH, Larson MJ, Murphy TK, Goodman WK. Development and psychometric evaluation of the Yale-Brown obsessive-compulsive scale\u2013Second Edition. Psychol Assess. 2010;22(2):223\u201332. https:\/\/doi.org\/10.1037\/a0018492.","journal-title":"Psychol Assess"},{"issue":"5","key":"6466_CR38","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/0005-7967(77)90042-0","volume":"15","author":"RJ Hodgson","year":"1977","unstructured":"Hodgson RJ, Rachman S. Obsessional-compulsive complaints. Behav Res Ther. 1977;15(5):389\u201395. https:\/\/doi.org\/10.1016\/0005-7967(77)90042-0.","journal-title":"Behav Res Ther"},{"key":"6466_CR39","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1037\/1040-3590.10.3.206","volume":"10","author":"EB Foa","year":"1998","unstructured":"Foa EB, Kozak MJ, Salkovskis PM, Coles ME, Amir N. The validation of a new obsessive-compulsive disorder scale: the obsessive-compulsive inventory. Psychol Assess. 1998;10:206\u201314.","journal-title":"Psychol Assess"},{"issue":"4","key":"6466_CR40","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1037\/1040-3590.14.4.485","volume":"14","author":"EB Foa","year":"2002","unstructured":"Foa EB, Huppert JD, Leiberg S, Langner R, Kichic R, Hajcak G, Salkovskis PM. The obsessive-compulsive inventory: development and validation of a short version. Psychol Assess. 2002;14(4):485\u201396.","journal-title":"Psychol Assess"},{"issue":"2","key":"6466_CR41","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1586\/ern.10.195","volume":"11","author":"K Benito","year":"2011","unstructured":"Benito K, Storch EA. Assessment of obsessive-compulsive disorder: review and future directions. Expert Rev Neurother. 2011;11(2):287\u201398. https:\/\/doi.org\/10.1586\/ern.10.195.","journal-title":"Expert Rev Neurother"},{"key":"6466_CR42","first-page":"37","volume":"3","author":"SW Kim","year":"1993","unstructured":"Kim SW, Dysken MW, Kuskowski M, Hoover KM. The Yale\u2013Brown Obsessive compulsive scale (Y\u2013BOCS) and the NIMH Global Obsessive compulsive scale (NIMH-GOCS): a reliability and validity study. Int J Meth Psychiatr Res. 1993;3:37\u201344.","journal-title":"Int J Meth Psychiatr Res"},{"key":"6466_CR43","unstructured":"Jbi.global. [Accessed 2 September 2024]. Available from: https:\/\/jbi.global\/critical-appraisal-tools"},{"key":"6466_CR44","doi-asserted-by":"publisher","first-page":"460","DOI":"10.4088\/JCP.v60n0603","volume":"60","author":"L de Haan","year":"1999","unstructured":"de Haan L, Linszen DH, Gorsira R. Clozapine and obsessions in patients with recent-onset schizophrenia and other psychotic disorders. J Clin Psychiatry. 1999;60:460\u20134.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"6466_CR45","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00213-013-3137-2","volume":"230","author":"J Cai","year":"2013","unstructured":"Cai J, Zhang W, Yi Z, Lu W, Wu Z, Chen J, et al. Influence of polymorphisms in genes SLC1A1, GRIN2B, and GRIK2 on clozapine-induced obsessive-compulsive symptoms. Psychopharmacology. 2013;230(1):49\u201355. https:\/\/doi.org\/10.1007\/s00213-013-3137-2.","journal-title":"Psychopharmacology"},{"issue":"4","key":"6466_CR46","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/s0010-440x(95)90071-3","volume":"36","author":"SN Ghaemi","year":"1995","unstructured":"Ghaemi SN, Zarate CA Jr, Popli AP, Pillay SS, Cole JO. Is there a relationship between clozapine and obsessive-compulsive disorder? A retrospective chart review. Compr Psychiatry. 1995;36(4):267\u201370. https:\/\/doi.org\/10.1016\/s0010-440x(95)90071-3.","journal-title":"Compr Psychiatry"},{"issue":"2","key":"6466_CR47","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1440-1819.2005.01362.x","volume":"59","author":"A Ertugrul","year":"2005","unstructured":"Ertugrul A, Anil Yagcioglu AE, Eni N, Yazici KM. Obsessive-compulsive symptoms in clozapine-treated schizophrenic patients. Psychiatry Clin Neurosci. 2005;59(2):219\u201322. https:\/\/doi.org\/10.1111\/j.1440-1819.2005.01362.x.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"3","key":"6466_CR48","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/01.ftd.0000211801.66569.80","volume":"28","author":"SK Lin","year":"2006","unstructured":"Lin SK, Su SF, Pan CH. Higher plasma drug concentration in clozapine-treated schizophrenic patients with side effects of obsessive\/compulsive symptoms. Ther Drug Monit. 2006;28(3):303\u20137. https:\/\/doi.org\/10.1097\/01.ftd.0000211801.66569.80.","journal-title":"Ther Drug Monit"},{"issue":"5","key":"6466_CR49","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.comppsych.2008.11.005","volume":"50","author":"AR Sa","year":"2009","unstructured":"Sa AR, Hounie AG, Sampaio AS, Arrais J, Miguel EC, Elkis H. Obsessive-compulsive symptoms and disorder in patients with schizophrenia treated with clozapine or haloperidol. Compr Psychiatry. 2009;50(5):437\u201342. https:\/\/doi.org\/10.1016\/j.comppsych.2008.11.005.","journal-title":"Compr Psychiatry"},{"issue":"6","key":"6466_CR50","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1177\/2045125311425971","volume":"1","author":"S Bleakley","year":"2011","unstructured":"Bleakley S, Brown D, Taylor D. Does clozapine cause or worsen obsessive compulsive symptoms? An analysis and literature review. Ther Adv Psychopharmacol. 2011;1(6):181\u20138. https:\/\/doi.org\/10.1177\/2045125311425971.","journal-title":"Ther Adv Psychopharmacol"},{"key":"6466_CR51","doi-asserted-by":"publisher","unstructured":"Grassi G, Poli L, Cantisani A, Righi L, Ferrari G, Pallanti S. Hypochondriasis and obsessive-compulsive disorder in schizophrenic patients treated with clozapine vs other atypical antipsychotics. CNS Spectr. 2014;19(4):340-6. Available from: https:\/\/doi.org\/10.1017\/S1092852913000795","DOI":"10.1017\/S1092852913000795"},{"key":"6466_CR52","doi-asserted-by":"publisher","unstructured":"Doyle M, Chorcorain AN, Griffith E, Trimble T, O\u2019Callaghan E. Obsessive compulsive symptoms in patients with schizophrenia on clozapine and with obsessive compulsive disorder: a comparison study. Compr Psychiatry. 2014;55(1):130-6. https:\/\/doi.org\/10.1016\/j.comppsych.2013.09.001. Epub 2013 Oct 1. PMID: 24209980.","DOI":"10.1016\/j.comppsych.2013.09.001"},{"key":"6466_CR53","doi-asserted-by":"publisher","first-page":"113665","DOI":"10.1016\/j.psychres.2020.113665","volume":"296","author":"G G\u00fcrcan","year":"2021","unstructured":"G\u00fcrcan G, \u015eenol \u015eH, Ya\u011fc\u0131o\u011flu AEA, Ertu\u011frul A. Clinical risk factors, phenomenology and the impact of clozapine induced obsessive compulsive symptoms. Psychiatry Res. 2021;296:113665. https:\/\/doi.org\/10.1016\/j.psychres.2020.113665. Epub 2021 Jan 16. PMID: 33465593.","journal-title":"Psychiatry Res"},{"issue":"7","key":"6466_CR54","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1017\/S003329172100492X","volume":"53","author":"K Parkin","year":"2023","unstructured":"Parkin K, Chen S, Biria M, Plaistow J, Beckwith H, Jarratt-Barnham I, et al. Clozapine-related obsessive-compulsive symptoms and their impact on wellbeing: a naturalistic longitudinal study. Psychol Med. 2023;53(7):2936\u201345. https:\/\/doi.org\/10.1017\/S003329172100492X.","journal-title":"Psychol Med"},{"key":"6466_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.sjpmh.2023.10.001","author":"JGHC Seow","year":"2023","unstructured":"Seow JGHC, Tan DHY, See YM, Yee JY, Ng BT, Tang C, et al. Obsessive-compulsive symptoms and disorder in clozapine-treated schizophrenia. Span J Psychiatry Ment Health. 2023. https:\/\/doi.org\/10.1016\/j.sjpmh.2023.10.001.","journal-title":"Span J Psychiatry Ment Health"},{"issue":"5","key":"6466_CR56","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1192\/bjp.2024.30","volume":"224","author":"E Fernandez-Egea","year":"2024","unstructured":"Fernandez-Egea E, Chen S, Sang\u00fcesa E, Gass\u00f3 P, Biria M, Plaistow J, et al. The role of psychosis and clozapine load in excessive checking in treatment-resistant schizophrenia: longitudinal observational study. Br J Psychiatry. 2024;224(5):164\u20139. https:\/\/doi.org\/10.1192\/bjp.2024.30.","journal-title":"Br J Psychiatry"},{"key":"6466_CR57","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00406-023-01593-y","volume":"274","author":"CL Morgenroth","year":"2024","unstructured":"Morgenroth CL, Kleymann P, Ripke S, Awasthi S, Wagner E, Oviedo-Salcedo T, et al. Polygenetic risk scores and phenotypic constellations of obsessive\u2013compulsive disorder in clozapine-treated schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2024;274:181\u201393. https:\/\/doi.org\/10.1007\/s00406-023-01593-y.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"6466_CR58","doi-asserted-by":"publisher","unstructured":"Wootton BM, Tolin DF. Obsessive\u2013compulsive disorder. In: Friedman HS, editor. Encyclopedia of Mental Health. 2nd ed. Academic; 2016. pp. 227\u201331. https:\/\/doi.org\/10.1016\/B978-0-12-397045-9.00090-2.","DOI":"10.1016\/B978-0-12-397045-9.00090-2"},{"key":"6466_CR59","doi-asserted-by":"publisher","unstructured":"Abramovitch A, Abramowitz JS, Riemann BC, McKay D. Severity benchmarks and contemporary clinical norms for the Obsessive-Compulsive Inventory-Revised (OCI-R). J Obsessive Compuls Relat Disord. 2020;27(100557):100557. Available from: https:\/\/doi.org\/10.1016\/j.jocrd.2020.100557","DOI":"10.1016\/j.jocrd.2020.100557"},{"issue":"3","key":"6466_CR60","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/bcpt.13384","volume":"126","author":"L Baandrup","year":"2020","unstructured":"Baandrup L. Polypharmacy in schizophrenia. Basic Clin Pharmacol Toxicol. 2020;126(3):183\u201392. https:\/\/doi.org\/10.1111\/bcpt.13384.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"11","key":"6466_CR61","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s40265-021-01556-4","volume":"81","author":"M L\u00e4hteenvuo","year":"2021","unstructured":"L\u00e4hteenvuo M, Tiihonen J. Antipsychotic polypharmacy for the management of schizophrenia: evidence and recommendations. Drugs. 2021;81(11):1273\u201384. https:\/\/doi.org\/10.1007\/s40265-021-01556-4.","journal-title":"Drugs"},{"issue":"1","key":"6466_CR62","doi-asserted-by":"publisher","first-page":"70","DOI":"10.4088\/JCP.07r03618","volume":"70","author":"R Cunill","year":"2009","unstructured":"Cunill R, Castells X, Simeon D. Relationships between obsessive-compulsive symptomatology and severity of psychosis in schizophrenia: a systematic review and meta-analysis. J Clin Psychiatry. 2009;70(1):70\u201382.","journal-title":"J Clin Psychiatry"},{"key":"6466_CR63","first-page":"439","volume":"53","author":"RW Baker","year":"1992","unstructured":"Baker RW, Chengappa KNR, Baird JW, Steingard S, Christ MAG, Schooler NR. Emergence of obsessive-compulsive symptoms during treatment with clozapine. J Clin Psychiatry. 1992;53:439\u201342.","journal-title":"J Clin Psychiatry"},{"key":"6466_CR64","doi-asserted-by":"publisher","first-page":"110506","DOI":"10.1016\/j.mehy.2021.110506","volume":"148","author":"DD Kim","year":"2021","unstructured":"Kim DD, Barr AM, Stewart SE, White RF, Honer WG, Procyshyn RM. Relationship between clozapine dose and severity of obsessive-compulsive symptoms. Med Hypotheses. 2021;148:110506. https:\/\/doi.org\/10.1016\/j.mehy.2021.110506. Epub 2021 Jan 21. PMID: 33515917.","journal-title":"Med Hypotheses"},{"issue":"4","key":"6466_CR65","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.rpsm.2017.06.002","volume":"10","author":"C Iglesias Garc\u00eda","year":"2017","unstructured":"Iglesias Garc\u00eda C, Iglesias Alonso A, Bobes J. Variaciones en las concentraciones plasm\u00e1ticas de clozapina en pacientes con esquizofrenia y trastorno esquizoafectivo. Rev Psiquiatr Salud Ment. 2017;10(4):192\u20136. https:\/\/doi.org\/10.1016\/j.rpsm.2017.06.002.","journal-title":"Rev Psiquiatr Salud Ment"},{"key":"6466_CR66","doi-asserted-by":"publisher","unstructured":"Haring C, Meise U, Humpel C, Saria A, Fleischhacker WW, Hinterhuber H. Dose-related plasma levels of clozapine: influence of smoking behaviour, sex and age. Psychopharmacology. 1989;99(Suppl). https:\/\/doi.org\/10.1007\/BF00442581.","DOI":"10.1007\/BF00442581"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-024-06466-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-024-06466-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-024-06466-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T15:51:28Z","timestamp":1737647488000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-024-06466-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6466"],"URL":"https:\/\/doi.org\/10.1186\/s12888-024-06466-9","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"assertion":[{"value":"22 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"71"}}